EIB provides €15 million to fund coronavirus research at IRBM
€15 million will be provided to IRBM to expand medical research and development to fight coronavirus and other infectious diseases.
IRBM World Cancer Day & Head of Oncology
This world cancer day we are here to raise awareness about the prevention, detection, and treatment of cancer.
We would like to take this opportunity to welcome our new Head of Oncology Alessandro Carugo, PhD. Prior to joining, Alessandro spent more than 10 years at The University of Texas MD Anderson Cancer Center, a world-renowned institution devoted to cancer patient care and prevention.
We would like to take this opportunity to welcome our new Head of Oncology Alessandro Carugo, PhD. Prior to joining, Alessandro spent more than 10 years at The University of Texas MD Anderson Cancer Center, a world-renowned institution devoted to cancer patient care and prevention.
Antios Therapeutics Announces Agreement with IRBM, INGM and OSR to Acquire Fourth-Generation HBV Capsid Assembly Modulators (CAMs)
Antios Therapeutics, Inc. (“Antios”), a clinical-stage biopharmaceutical company developing innovative therapies to treat and cure chronic hepatitis B virus (HBV), and IRBM, a drug discovery and early development research institute and global contract research organization, announced today they entered into an agreement for Antios to purchase the IP rights to a novel series of fourth-generation capsid assembly modulators (CAMs) being developed for the treatment of HBV.
Discovery and characterization of novel peptide inhibitors of the NRF2/MAFG/DNA ternary complex for the treatment of cancer
Our Peptide Chemistry team, in collaboration with scientists at Merck and Co., reported on the design, synthesis and characterization of potent and stable peptides able to inhibit the binding of NRF2-MAFG heterodimeric transcription factor to Antioxidant Response Element (ARE) DNA sequence.
Targeting of eIF6-driven translation induces a metabolic rewiring that reduces NAFLD and the consequent evolution to hepatocellular carcinoma
At IRBM we are passionate about helping companies develop medicines in a wide range of diseases and our scientists support the fundamental understanding of disease mechanisms. Science is about collaboration, and publication is an integral part of the scientific process.
IRBM & collaborators publish on techniques for characterizing peptides in Type 2 diabetes and a peptide drug discovery program for Huntington’s disease
Nowadays, there is a strong drive to explore new areas of chemical space in search of innovative ways to bind and modulate challenging biological targets. At IRBM our peptide chemistry team has extensive expertise in peptide and macrocyclic drug discovery in various therapeutic areas.
IRBM to collaborate with MSD to develop peptides against coronavirus
Builds on Research to Combat Severe Acute Respiratory Syndrome (SARS)
Rome, Italy – IRBM, a global Contract Research Organization today announced a new research collaboration agreement with MSD (tradename of Merck & Co., Inc., Kenilworth, NJ, USA) to identify and develop novel peptide therapeutics active against different strains of coronavirus, including SARS-CoV-2.
Rome, Italy – IRBM, a global Contract Research Organization today announced a new research collaboration agreement with MSD (tradename of Merck & Co., Inc., Kenilworth, NJ, USA) to identify and develop novel peptide therapeutics active against different strains of coronavirus, including SARS-CoV-2.
In Memory of Maurizio Botta: His Vision of Medicinal Chemistry
IRBM’s medicinal chemists are incredibly proud to have contributed 3 articles to a special issue of the ACS Medicinal Chemistry Letters in memory of Professor Maurizio Botta. Many of our chemistry team were former students of the professor and are therefore thrilled to be part of this tribute.
IRBM supporting the effort to cope with the impact of coronavirus
There are many ways to face the impact of coronavirus. Due to the worldwide pandemic, there is a blood shortage in several hospitals. The staff at IRBM set up, in partnership with Ema-Roma, a Blood Donation Day. This highly worthwhile…
IRBM’s Chief Science Officer, Carlo Toniatti is featured in the Medicine Maker’s Power List
Carlo joins other leading authorities in drug discovery and development as part of the Biopharmaceuticals category in the Medicine Maker Power List. In his interview he reviews future trends in drug development and some of the defining moments of his…